A critical advance in cancer research is emerging with the use of mini-antibodies to re-engage dysfunctional p53. This crucial malignant inhibitor protein is frequently disabled in several kinds of malignancies, https://sociallweb.com/story7516614/nanobodies-reactivate-p53-a-potential-approach-for-cancer-treatment